Abstract: Persistent pulmonary hypertension in newborn (PPHN) is a serious and possibly fatal syndrome characterized by sustained foetal elevation of pulmonary vascular resistance at birth. PPHN may manifest secondary to other conditions as meconium aspiration syndrome, infection and congenital diaphragmatic hernia. This MiniReview provides the reader with an overview of current and future treatment options for patients with PPHN without congenital diaphragmatic hernia. The study is based on systematic searches in the databases PubMed and Cochrane Library and registered studies on Clinicaltrials.gov investigating PPHN. Inhaled nitric oxide (iNO) is well documented for treatment of PPHN, but 30% fail to respond to iNO. Other current treatment options could be sildenafil, milrinone, prostaglandin analogues and bosentan. There are several ongoing trials with sildenafil, but evidence is lacking for the other treatments and/or for the combination with iNO. Currently, there is no evidence for effect in PPHN of other treatments, for example tadalafil, macitentan, ambrisentan, riociguat and selexipag used for pulmonary arterial hypertension in adults. Experimental studies in animal models for PPHN suggest effect of a series of approaches including recombinant human superoxide dismutase, L-citrulline, Rho-kinase inhibitors and peroxisome proliferator-activated receptor-c agonists. We conclude that iNO is the most investigated and the only approved pulmonary vasodilator for infants with PPHN. In the iNO non-responders, sildenafil currently seems to be the best alternative either alone or in combination with iNO. Systematic and larger clinical studies are required for testing the other potential treatments of PPHN.
Persistent pulmonary hypertension of the newborn (PPHN) is a serious syndrome characterized by sustained foetal elevation of pulmonary vascular resistance at birth. The syndrome is seen in two of 1000 live-born infants and is associated with a normal or low systemic vascular resistance [1] . Newborns with PPHN are at risk of severe complications as asphyxia, chronic lung disease, neurodevelopmental sequelae and death [2] .
The pulmonary transition at birth relies on an immediate drop in pulmonary vascular resistance and an eight to 10 times increase in pulmonary blood flow. Stimuli known to contribute to the pulmonary vasodilation and hence the drop in pulmonary vascular resistance are increased PO 2 , rhythmic distension of the lungs, drainage and absorption of foetal lung liquid, and increased production of different vasoactive mediators. The effects of especially increased PO 2 , increased blood flow or shear stress and ventilation are partly dependent on the activation of endothelial nitric oxide synthase. The activation of endothelial nitric oxide synthase resulting in the production of the vasoactive mediator nitric oxide is responsible for nearly 50% of the fall in pulmonary vascular resistance. Phosphodiesterase type 5 (PDE 5) is an enzyme that hydrolyses cyclic GMP and hence inhibits the vasodilatation induced by nitric oxide. Thus, PDE 5 limits the drop in pulmonary vascular resistance. PDE 5 is highly expressed in lung tissue during foetal life and a key regulator of perinatal pulmonary circulation along with nitric oxide [3] .
The pathophysiology of PPHN is based on changes in pulmonary vascular structure and function. An elevated pulmonary vascular resistance may result from pulmonary vasoconstriction, structural remodelling of the pulmonary musculature, intravascular obstruction and lung hypoplasia [1] . It may be secondary to other diseases as meconium aspiration syndrome, infection and congenital diaphragmatic hernia. Preterm and birth by Caesarean versus natural delivery increase the risk of PPHN [3] . Antenatal exposure to selective serotonin-reuptake inhibitors used to treat maternal depression has been associated with the development of PPHN [4] . Another known risk factor is antenatal exposure to smoke. The use of non-steroidal anti-inflammatory drugs, especially ibuprofen, naproxen and aspirin during pregnancy is associated with PPHN [5] . This is problematic because of the easy access to over-the-counter non-steroidal anti-inflammatory drugs. Furthermore, stress or pain, perinatal malnutrition and hyperoxia may impair the pulmonary vascular adaptation at birth [3] . Infants with PPHN secondary to congenital diaphragmatic hernia may respond differently to treatment and should be analysed separately [6] .
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Clinically, PPHN shows varying degrees of hypoxemic respiratory failure. PPHN is characterized by labile hypoxaemia and pre-post ductal saturation gradient which manifests itself as differential cyanosis [7] . Hypoxaemia is due to intrapulmonary shunting secondary to V/Q mismatch and/or extrapulmonary right-to-left shunting across persistent foetal channels because of the increased pulmonary vascular resistance/systemic vascular resistance ratio [1] . Echocardiography is the gold standard investigation for the diagnosis of PPHN [8] . The echocardiographic findings are right ventricular hypertrophy, deviation of the interventricular septum to the left, tricuspid regurgitation and right-to-left or bidirectional shunting across patent foramen ovale, and patent ductus arteriosus [7] .
Inhaled nitric oxide (iNO) is the only approved specific pulmonary vasodilator for infants in the USA [9] . No literature describing other approved vasodilators has been found; however, literature describing clinical use of other treatments than iNO has been found. It is a costly intervention, and approximately 30% of neonates with PPHN fail to respond to iNO. Some may even experience a rebound pulmonary hypertension due to suppression of endogenous nitric oxide production [9, 10] . Therefore, knowledge about the effects and the clinical use of other treatments than iNO may be important for the survival of the infant [7] [8] [9] . Some treatment options for PPHN have previously been described [9] , but without a description of the quality of evidence or implications for future research for each treatment. This MiniReview provides the reader with an updated systematic overview of current available treatments. Furthermore, implications for future research for each treatment will be discussed. Adverse events of each drug choice will be reviewed. This is important information in situations where non-responders to iNO may be fatally challenged by adverse events of the treatment.
The objective of this MiniReview was to examine the current available and emerging future treatment options for persistent pulmonary hypertension of the newborn without congenital diaphragmatic hernia.
Methods
Eligibility criteria: Following the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence, all studies rated levels 1-5 were considered eligible. As far as possible, eligible studies should be from 2008 or newer, but if the available data were limited due to the low prevalence of PPHN, older studies would be considered eligible, too.
Information sources: PubMed -by the National Center for Biotechnology Information, U.S. National Library of Medicine. The Cochrane Library -a collection of six databases that contain different types of high-quality, independent evidence to inform healthcare decision-making, and a seventh database that provides information about Cochrane groups. Clinicaltrials.gov is a database of privately and publicly funded clinical studies conducted around the world, run by U.S National Library of Medicine. Pro.medicin.dk is a website and database containing information about drugs and therapeutic instructions. It is issued by DLI A/S (Dansk Laegemiddel Information A/S). PubChem is an open chemistry database at the National Institutes of Health, collecting information on chemical structures, identifiers, chemical and physical properties, biological activities, patents, health, safety, toxicity data and many others.
The last literature search was performed on 14 February 2018. On PubMed, the search strategy was 'Persistent Pulmonary Hypertension of the Newborn'. This resulted in 2130 items. With a 'Clinical Trial' filter, 111 items were found. With no filter and the addition of MeSH Term 'Animals, Newborn', 153 items were collected. For finding indepth literature describing each treatment, a search for '*Drug Name* AND Persistent Pulmonary Hypertension of the Newborn' was carried out, for example 'Treprostinil AND Persistent Pulmonary Hypertension of the Newborn'. Searching for 'Persistent Pulmonary Hypertension of the Newborn' in Cochrane Library gave nine items and using the same search on Clinicaltrials.gov resulted in 31 items.
Study selection: Cf. the objective of this MiniReview, only studies investigating treatments for PPHN without congenital diaphragmatic hernia were included. To be included, the individual study should clearly state the diagnosis of PPHN without congenital diaphragmatic hernia in the patient group investigated. Systemic reviews and metaanalysis found on The Cochrane Library were excluded if no eligible study had been found. Studies from Clinicaltrials.gov with the status of 'withdrawn' or with an objective different from investigating a treatment were excluded.
Therapy of PPHN

General management.
The general management of PPHN comprises the treatment of hypoxaemia with oxygen supplementation and the underlying condition besides maintaining haemoglobin, glucose, intravascular volume, temperature and electrolytes at normal levels [2, 8] . High-frequency ventilation allows ventilation with small tidal volumes. Combined with iNO in a randomized multi-centre trial, high-frequency ventilation was shown to be more successful than treatment with high-frequency ventilation or iNO alone [11] . This management may be considered in neonates with PPHN before advancing to extra corporeal membrane oxygenation (ECMO). ECMO is an extremely complex and invasive technique providing life support in severe, but potentially reversible respiratory failure. The technique oxygenates blood outside the body. Infants with PPHN are well suited to ECMO as the improved oxygenation and physiological stability improves pulmonary blood flow without risking further barotrauma [12] . When compared to conventional ventilation support as presented in a Cochrane review by Mugford et al. [12] , ECMO was shown to reduce mortality without an increased risk of severe disability in infants with PPHN.
Inhaled nitric oxide.
Nitric oxide (NO) is produced from the nitrogen of L-arginine and molecular oxygen by the endothelial nitric oxide synthase enzyme (eNOS) in vascular endothelial cells. NO diffuses through the endothelium to the vascular smooth muscle and activates soluble guanylyl cyclase (sGC) leading to the production of cyclic guanyl monophosphate (cGMP), which activates the cGMP-dependent protein kinase or protein kinase G (PKG). PKG stimulates myosin phosphatase associated with dephosphorylation of myosin light chain and activates potassium channels followed by hyperpolarization, and reduction of the influx of calcium. This leads to vasodilation. iNO acts locally as pulmonary vasodilator ( fig. 1 ). Thus, iNO is an obvious choice in the treatment of PPHN.
Barrington et al. [6] compared iNO with control in neonates with PPHN by meta-analysing 17 randomized controlled trials (RCTs). Participants were newborn infants (<1 month of age) with hypoxaemia suspected to be due to lung disease, pulmonary hypertension with right-to-left shunting or both. The inclusion criterion was studies in term and near-term infants (>34 weeks of gestational age). Exclusions were infants with intracardiac shunting due to structural congenital heart disease. They reported no significant difference in death before hospital discharge between the groups. A significant reduction in the use of ECMO before hospital discharge was found, indicating that the number needed to treat with iNO for an additional beneficial outcome to prevent 1 neonate from requiring ECMO was 5. Oxygenation was significantly improved in infants treated with iNO, and the oxygenation index 30-60 min. after the start of treatment was significantly lower in the iNO group. PaO 2 30-60 min. after treatment was significantly higher when treated with iNO. Furthermore, neonates who received iNO were not at increased risk of neurodevelopmental sequelae and did not experience increased post-discharge pulmonary complications. The meta-analysis reported that clinical or echocardiographic evidence of PPHN was not present in all the included studies. Therefore, it was concluded that iNO should be considered for near-term infants with hypoxic respiratory failure with or without clear evidence of PPHN. The quality of evidence was rated moderate to high. To the author's knowledge, iNO is the most investigated treatment for PPHN.
Currently, iNO is not believed to have systemic adverse events due to systemic inactivation by interactions with haemoglobin [6] (table 1) . That said, an interaction between iNO and haemoglobin may result in the creation of methaemoglobin. Methaemoglobin levels should be carefully monitored as it is toxic and causes a left shift in the O 2 -Haemoglobin dissociation curve resulting in worsening of hypoxia [13] . Significant methaemoglobinaemia has been reported in a case of an overdose of iNO in a neonate [14] . Increased toxicity has not been shown after long-term treatment iNO. A reaction between a superoxide and nitric oxide creates peroxynitrite, which may result in membrane lipid peroxidation. The formation of the end product nitrite may induce bronchoconstriction and cough. Furthermore, NO inhibits platelet aggregation and adhesion influencing the hemostasis.
Phosphodiesterase inhibitors. PDE 5 is responsible for breaking down cGMP in the smooth muscle cell. Inhibiting PDE 5 extends the duration of activity of cGMP resulting in relaxation of the smooth vascular muscle. Thus, the inhibition of PDE 5 leads to vasodilation. Dipyridamole is a PDE 5 inhibitor but has shown significant systemic adverse effects in newborn lamb models with persistent pulmonary hypertension [15] . Sildenafil ( fig. 2A ) is also a PDE 5 inhibitor and has been studied in neonatal pig models of pulmonary hypertension secondary to meconium aspiration, showing no adverse systemic effects and a vasodilating efficiency at Fig. 1 . Pharmacodynamics of current and emerging treatments. PDE5, phosphodiesterase-5; PDE3, phosphodiesterase-3; GMP, guanylyl monophosphate; AMP, adenosine monophosphate; cGMP, cyclic guanylyl monophosphate; cAMP, cyclic adenosine monophosphate; sGC, soluble guanylyl cyclase; AC, adenylyl cyclase; IP, PGI 2 -receptor; EP, PGE 1 -receptor; PGIS, prostacyclin synthase; COX, cyclooxygenase; eNOS, nitric oxide synthase; ET-1, endothelin; rET B , relaxant endothelin receptor; cET B , contractile endothelin receptor and ET A , endothelin receptor; rhSOD, recombinant human superoxide dismutase; L-arg., L-arginine; SNAT1, sodium-coupled neutral amino acid transporter.
least as good as iNO [16] . Sildenafil has become a common agent in the chronic management of pulmonary hypertension in adults [17] and is the most common enteral pulmonary vasodilator for children with pulmonary arterial hypertension [9] . Therefore, sildenafil may be a promising choice of treatment for PPHN when iNO is not available ( fig. 1) .
Kelly et al. [10] , a Cochrane review, investigated the efficacy and safety of sildenafil for treatment of PPHN. They included term and near-term neonates (postnatal age <28 days after reaching gestational age of 40 weeks) with either primary or secondary PPHN. The included studies based the diagnosis on clinical findings with or without echocardiographic confirmation. Exclusion criteria were infants with structural genital heart disease with exception of patent foramen ovale and patent ductus arteriosus. Sildenafil was compared to either placebo or no treatment, versus another pulmonary vasodilator, and sildenafil and another pulmonary vasodilator versus another pulmonary vasodilator and placebo. This resulted in five included studies. When compared to placebo, a significant reduction in mortality in the sildenafil group was found based on three studies. No trials reported significant difference in mortality upon comparison of the sildenafil group versus the active control group, or when iNO was administered to both groups. Oxygenation index and PaO 2 suggested steady improvement after the first sildenafil dose, but without statistical significance. No adverse events were reported. In a small open-label study testing the pharmacokinetics of sildenafil in infants with PPHN, the following adverse events were reported: hypotension, development of patent ductus arteriosus with left-to-right shunting, pneumothorax, total anomalous pulmonary venous return, hypotension associated with trisomy 21 and adrenal insufficiency [18] (table 1). Other known adverse events of PDE 5 inhibitors are visual, musculoskeletal, hearing and vestibular disorders [19] . The available literature regarding sildenafil as treatment of PPHN is limited and low-rated regarding quality of evidence due to the imprecision of small studies and lack of methodological features. Despite the lack of literature, sildenafil is currently used as acute adjuvant to iNO in NO-resistant PPHN and as an acute primary treatment of PPHN when iNO is not available or contraindicated [9] . Further RCTs investigating sildenafil should be performed to increase the quality of evidence. Sildenafil could either be investigated versus placebo or iNO. Doubleblinding of future studies would be preferred to raise the evidence, and the studies should be conducted in such manner that follow-up will be possible for investigating long-term effects.
Tadalafil is also a PDE-5 inhibitor approved for use in adults with pulmonary arterial hypertension and has larger selectivity for PDE5 and longer half-life. One animal study, investigating tadalafil in seven piglets with induced acute pulmonary hypertension, showed a reduction in PVR and lung shunt fraction as well as an increase in cardiac output and arterial oxygenation, when oral tadalafil was administered [20] . No human study investigating tadalafil for use in PPHN has been found. One open-label study investigating tadalafil for use in 25 children with pulmonary arterial hypertension has been found. Nineteen patients were administered tadalafil and six patients had been on sildenafil for longer than 6 months. A transition from sildenafil to tadalafil showed a significant clinical improvement. This study found that tadalafil may be more effective than sildenafil. The most frequent reported adverse event was nausea (table 1) [21] . Even though tadalafil has a low affinity for phosphodiesterase-6 in • Systemic hypotension photoreceptors, visual disturbances have been reported, too. Musculoskeletal, hearing and vestibular disorders have been reported, but these are suggested to be less likely associated with tadalafil than sildenafil [19] . To investigate tadalafil in PPHN, future studies must be conducted.
Phosphodiesterase-3 (PDE 3) is responsible for the breakdown of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells and myocardium. By inhibiting PDE 3, the intracellular cAMP level increases leading to vasodilation and may increase cardiac contractility. Milrinone ( fig. 2B ) is a PDE 3 inhibitor and vasodilator ( fig. 1) . In rat models of pulmonary hypertension, milrinone has shown to have an additive pulmonary vasodilating effect when administered with iNO [22] . In lamb models with PPHN, milrinone exhibited an enhancing effect of the vasodilation induced by prostacyclin. Thus, a combination therapy of milrinone and prostacyclin may be a new option of treatment for PPHN [23, 24] . An open-label study [25] investigated milrinone in neonates with PPHN and suboptimal response to iNO. Inclusion criteria were neonates with a gestational age larger than 34 weeks and <10 postnatal days of life, echocardiographic diagnosis of PPHN, indwelling arterial line for obtaining blood samples, and absence of a congenital heart defect excluding small atrial septal defects and ventricular septal defects. A total of 11 neonates were included. The study showed that the administration of milrinone was associated with improvement in pulmonary arterial hypertension and blood flow. Previously, adverse events of hypotension, thrombocytopenia and arrhythmia have been reported after the use of milrinone, but these were not confirmed due to no reports of adverse events in the study (table 1) [25] . Based on these data, milrinone should not be interpreted as an alternative to iNO due to the lack of a control group. Future RCTs should be conducted to investigate mortality, oxygenation index improvement or requirement for ECMO. Double-blinding would be preferred as well as a longterm follow-up for investigating sequelae.
Prostaglandin analogues.
The arachidonic acid-prostacyclin pathway plays an important role in vascular pulmonary muscle tonus. By activating adenylyl cyclase prostaglandins increase the intracellular cAMP concentration in vascular smooth muscle cells and lead to vasodilation ( fig. 1 ). Prostacyclin derivates (e.g. Iloprost; fig. 2C ) are used to treat pulmonary arterial hypertension in adults.
Janjindamai et al. [26] conducted a retrospective medical records review of 33 infants diagnosed with PPHN by echocardiography. They found that intravenous iloprost significantly reduced the oxygenation index. They showed that the need of inotropic support increased. When administered in adult patients with pulmonary arterial hypertension in an open-label study, the most common adverse events were headache and cough (table 1) . One patient experienced hypotension [27] . The use of aerosolised iloprost has shown a subsequent rapid tolerance development to the vasodilatory effect [28] . In another retrospective study of 47 infants with PPHN [29] , iloprost seemed to be more effective than sildenafil in terms of time to and duration of a clinical response.
A retrospective cohort study [30] of 142 infants between ≤10 days and ≥34 weeks of gestation revealed the use of prostaglandin E 1 in infants with PPHN is significantly associated with a shortened length of hospitalization. No statistically significant difference in mortality between PGE 1 -treated and non-PGE 1 -treated infants was found. The final diagnosis of PPHN was based on echocardiography.
In a small phase I/II open-label clinical trial [31] , 21 infants with PPHN born at >34 weeks of gestation at an age of <2 weeks were administered inhaled alprostadil, which is a PGE 1 analogue. Echocardiography was not a required diagnosis for enrolment, and all infants were treated with surfactant prior to enrolment. Alprostadil treatment revealed an improvement in PaO 2 without toxic adverse events. No serious adverse events associated to alprostadil were reported. A RCT tried to investigate this further but failed to include enough patients [32] . In bovine coronary artery smooth muscle cells, prostaglandin E 2 has shown not to develop tolerance to antimitogenic actions within 24 hr, as it was shown for iloprost [33, 34] . When administered to patients with impaired renal function, alprostadil has shown adverse events as hypotension, nausea, vomiting, fatigue and skin symptoms (table 1) [35] .
Epoprostenol is a prostacyclin analogue used for treatment of pulmonary arterial hypertension in adults. The found data regarding the use of epoprostenol in neonates with PPHN are limited to two old and small studies and case reports. The two studies were consistent in reporting beneficial outcome of the use of epoprostenol in neonates with PPHN [36, 37] . When administered in healthy adults, the most common adverse event of epoprostenol was headache [38] . When administered intravenously in adults with pulmonary arterial hypertension, adverse events of jaw pain, diarrhoea, catheter-related infections and thrombosis have been reported (table 1) [39] . Drug tolerance was reported for continuous intravenous treatment with epoprostenol in pulmonary hypertension [40] .
Treprostinil is a known prostacyclin analogue. The data on the use of treprostinil are limited. Two case reports described the administration of treprostinil in two neonates with early onset sepsis and PPHN who did not respond to iNO. Within 6-12 hr after the treatment with treprostinil, both patients showed clinical improvement. No systemic adverse events were observed [41] . When administered intravenously in adults with pulmonary arterial hypertension, the most common reported adverse events were infusion-site erythema and pain [42] . When administered orally in adults, adverse events were headache, diarrhoea, nausea, flushing and jaw pain (table 1) [43] .
Selexipag, a prostacyclin receptor agonist, is an orally available prodrug which has shown significantly improvements in the treatment of pulmonary arterial hypertension in adults [44, 45] . Thus, selexipag may have a future potential in the treatment of PPHN [46] [47] [48] [49] . No animal studies investigating selexipag in PPHN have been found. In a large double-blinded and randomized global study testing selexipag used in pulmonary arterial hypertension, the most frequently reported adverse events leading to treatment interruption were headache, diarrhoea, nausea, vomiting and pain in extremity (table 1) [50] .
Although prostaglandins are well-known pulmonary vasodilators, sufficient literature regarding treatment of PPHN is non-existent. fig. 2D ) is an ET-1 antagonist acting at both receptors ( fig. 1 ). It has proven to be efficient in adults with pulmonary hypertension [51] . In newborn lamb models, PPHN was associated with increased ET A -mediated vasoconstriction and a loss of ET B -mediated vasodilation [52, 53] . Furthermore, elevated plasma levels of ET-1 had been reported in newborn infants with pulmonary hypertension [54, 55] . Therefore, the use of bosentan or other endothelin receptor antagonists to treat PPHN may be an effective alternative to iNO.
Endothelin receptor antagonists.
More et al. [56] identified in a systematic review of randomized, cluster-randomized or quasi-randomized controlled trials two studies that evaluated the efficacy and safety of endothelin receptor antagonists in term and late pre-term infants with PPHN. Both studies reported that bosentan was well tolerated and that there were no major adverse events. The problem with the studies investigating PPHN is the low amounts of patients. Thus, more rare and serious adverse events are not detected. In adults, treatment with bosentan for pulmonary arterial hypertension has shown to cause an abnormal liver function and elevations of alanine aminotransferase and aspartate aminotransferase, indicating hepatotoxicity [57] [58] [59] . Adverse events of nasopharyngitis have also been reported in patient groups treated with bosentan [59] . Other reported adverse events are headache, flushing and peripheral oedema (table 1) [60] .
In the first study, bosentan was used as the sole pulmonary vasodilator. iNO and ECMO were not available in the setting. Mohamed et al. [61] reported no significant difference in death from any cause prior to hospital discharge or prior to 28 days of life between bosentan-treated infants and a placebo control group. The infants treated with bosentan showed a significant benefit when comparing at least 20% improvement in oxygenation index within 72 hr of treatment to the placebo control group. Furthermore, the bosentan group showed a significant benefit in improved oxygenation index by at least 20% at the end of the treatment. The total duration of mechanical ventilation was significantly lower in the bosentan group.
There was no difference in development of cerebral palsy or hearing impairment between the groups. However, a trend to a higher incidence of other adverse neurodevelopmental sequelae was found in the placebo group. They did not report the length of hospitalization, other adverse events or other information on cognitive and neurodevelopmental disability at 18-24 months. This study had no available iNO for treatment. No hepatotoxicity was reported.
In the FUTURE-4 trial, a multi-centre study where iNO and ECMO were available, bosentan was used as an adjunct therapy to iNO. Steinhorn et al. [62] reported no significant difference in the requirement for ECMO prior to hospital discharge between the groups. There was no significant difference in duration of iNO therapy or total duration of mechanical ventilation. The authors reported that bosentan did not affect systemic blood pressure adversely, but no details were given. No hepatotoxicity was reported.
However, for both studies, the overall quality rating of evidence was low due to small sample size of the included studies, the numerical imbalance between the groups due to randomization and attrition, and unclear risk of bias on some of the important domains [56] . More RCTs regarding the efficacy and safety of bosentan as alternative to iNO in the treatment for PPHN should be conducted.
Macitentan is a new dual ETRA showing potential in the treatment of pulmonary arterial hypertension. Macitentan has been reported to have less adverse effects e.g. hepatotoxicity compared to bosentan (table 1) ; therefore, macitentan may have a future potential in the treatment of PPHN [63] [64] [65] . That said, one case report describing serious liver injury after macitentan treatment for adult pulmonary arterial hypertension has been found [66] , indicating the importance of registering adverse events of ETRAs in future studies.
Ambrisentan is an ETRA used in the treatment of pulmonary arterial hypertension in functional WHO class II-III [67, 68] . No studies investigating ambrisentan in neonates with PPHN have been found. In an ongoing study (NCT01406327) of 702 patients with pulmonary arterial hypertension treated with ambrisentan, interim results have shown that common adverse events are anaemia, peripheral oedema, headache, face oedema, abnormal hepatic function and epistaxis [69] .
Soluble guanylyl cyclase activators/stimulators. As previously described, iNO acts on sGC, but resistance to NO and tolerance may limit the vasodilation. Thus, by activating sGC directly with an activator, a relaxation of vascular smooth muscle cells may occur independently of NO ( fig. 1) . The sGC stimulator riociguat ( fig. 2E ) (BAY 63-2521 [70] ) is used for pulmonary arterial hypertension as monotherapy or in combination with ETRA or prostanoids [71] . Information regarding the use of riociguat in children with pulmonary arterial hypertension is missing [71, 72] . No studies investigating sGC activators/stimulators as treatment of PPHN in neonates were found. Spreemann et al. [73] reported positive results in a case using oral riociguat in combination with bosentan in a child with supra-systemic pulmonary hypertension at the age of 3 years. In adult patients with chronic thromboembolic pulmonary hypertension, the most common adverse events of treatment with riociguat were hypotension, headache, nasopharyngitis and peripheral oedema [74, 75] . Other reported adverse events of riociguat are musculoskeletal, gastrointestinal, vestibular and haemorrhagic disorders ( [76] . In neonatal lamb models with PPHN, sGC activators has been shown to cause a significantly greater fall in PVR than either 100% O 2 or iNO [77, 78] . Furthermore, a study in foetal lambs has indicated an impaired sGC activity as a contributing factor in the pathogenesis of PPHN [77] .
These findings suggest that sGC stimulators and activators may have a therapeutic potential as alternative or adjuvant therapy for infants with PPHN who are non-responsive to iNO and O 2 . By conducting a double-blinded RCT in the future, the efficacy of riociguat in the treatment of PPHN without CDH could be enlightened. A subsequent follow-up would be necessary to evaluate long-term effects.
Rho-kinase inhibitors.
RhoA is a small GTPase increasing Rho-kinase activity leading to phosphorylation of myosin light chain and vasoconstriction in vascular smooth muscle ( fig. 1 ). Rho-kinase activity has shown to modulate contraction of vascular smooth muscle cells in the systemic and pulmonary circulation [79] . In foetal lambs, Rho-kinase activity has been shown to maintain the high PVR [80] .
The RhoA-Rho-kinase pathway is involved in vasoconstriction, when eNOS is inhibited which may indicate Rho-kinase inhibitors as a future treatment [80] . Furthermore, increased Rho-kinase activity was found to lead to impaired angiogenesis in foetal lambs [79] . Therefore, the activity of the Rhokinase may be a potential future target for treatment of PPHN. A newer animal study using foetal lambs with PPHN has suggested interactions between the Rho-kinase activity and peroxisome proliferator-activated receptor-c (PPAR-c). By inhibiting the Rho-kinase in foetal lambs with decreased PPAR-c activity, the PPAR-c activity was restored to normal. These findings suggest that an inhibition of the Rho-kinase combined with activation of PPAR-c results in a restored growth of pulmonary arterial smooth muscle cells [81] . Compounds inhibiting the Rho-kinase are Y-27632 and fasudil (HA-1077) [80] . Fasudil is registered for the treatment of pulmonary arterial hypertension in Japan. Infused fasudil has shown to improve pulmonary hemodynamics without significant toxicity [82] . Inhaled fasudil has shown to be at least as effective as iNO [83] . Administered in a double-blinded, placebo-controlled clinical trial, fasudil hydrochloride (AT-877ER) was shown to improve hemodynamics in adult patients with pulmonary arterial hypertension [84] . No studies investigating fasudil in PPHN have been found. Fasudil is also used for preventing cerebral vasospasms in patients undergoing surgery for subarachnoid haemorrhage and when investigated versus placebo in these patients, no significant difference in adverse events was found [85] . Some studies report no clinical significant systemic hypotension caused by fasudil [82, 86, 87] whereas a newer animal study has concluded fasudil is not a useful targeting drug due to a significant systemic hypotension (table 1) [88] . No larger clinical trial investigating fasudil has been found. Future studies of fasudil could determine the profile of adverse events. Fasudil has a potential in the treatment of pulmonary arterial hypertension, and future research should address the effect of fasudil versus placebo or iNO in PPHN in a large double-blinded RCT.
Clinical trials.
Clinical trials concerning the pharmaceutical treatment on PPHN can be found on Clinicaltrials.gov. Details regarding studies registered on Clinicaltrials.gov are presented in table 2 for sildenafil, bosentan, prostaglandins, milrinone and for iNO. Most of these studies aim to assess the safety and treatment effect of the drugs in infants with PPHN to find optimal starting doses as well as therapy timescales. Further, some trials in adults have investigated an additive effect of combining prostacyclins with sildenafil or bosentan. First results seem to be promising with improvement in hemodynamic parameters [43] . Emerging targets and therapies for PPHN are currently under investigation. Table 3 summarizes implications of future research.
Future Treatments
This section will describe possible future treatments based on findings in animal studies. These compounds could be researched in future phase 0-1 studies. Some drugs are used in other treatments, for example rosiglitazone in diabetes mellitus type II meaning that some adverse events and pharmacokinetics already are known.
Antioxidants.
Mechanical ventilation as treatment option for PPHN may result in formation of reactive oxygen species which can inactivate NO and cause further vasoconstriction ( fig. 1) . In foetal lamb models with PPHN, intratracheal recombinant human superoxide dismutase (rhSOD) has shown to improve oxygenation and reduce oxidation and vasoconstriction [89] . In another study, inhaled rhSOD was shown to enhance the effect of iNO in foetal lambs with PPHN [90] . In foetal lambs, rhSOD has also been shown to restore eNOS coupling [91] . These findings indicate that rhSOD could be a future therapy adjuvant to iNO for PPHN.
L-citrulline.
L-citrulline is a L-arginine-NO precursor. Through a two-step enzymatic process, L-citrulline is converted to L-arginine which is directly channelled to eNOS for efficient NO production [92, 93] (fig. 1) . Furthermore, L-citrulline stimulates the recoupling of eNOS which improves NO production [94] . In piglet models, L-citrulline is transported into pulmonary arterial endothelial cells (PAEC) by a sodium-coupled neutral amino acid transporter (SNAT1). The activity of SNAT1 modulates the L-citrulline-induced NO production, which increases in hypoxic PAEC due to an increased expression of SNAT1 within 24, 48 and 72 hr of hypoxic conditions in piglets [95, 96] . Furthermore, it has been demonstrated that an impaired L-citrulline-L-arginine-NO pathway is involved in the pathogenesis of pulmonary hypertension [97] . Another study in piglet models has shown that rescue treatment with L-citrulline improves pulmonary hypertension induced by hypoxia [94] . These findings suggest that by increasing NO production, supplemental L-citrulline and modulators of SNAT1 may be emerging alternate therapies for infants with PPHN. In 25 adult patients with idiopathic pulmonary hypertension or Eisenmenger syndrome, oral L-citrulline has shown a reduction in PVR [98] . No clinical trials regarding L-citrulline use in infants had been performed until today.
PPAR-c agonists.
PPAR-c regulates smooth muscle cell proliferation and inhibits vascular remodelling ( fig. 1) . In a mouse model, it has been shown that a selective deletion of the PPAR-c gene results in spontaneously developed pulmonary arterial hypertension [99] . Furthermore, activation of PPAR-c resulted in a decreased proliferation of pulmonary arterial smooth muscle cells in vitro [99] . In foetal lamb models with PPHN, ET-1 has shown to decrease PPAR-c signalling which contributes to dysfunction of pulmonary arterial endothelial cells [100] . In the same study, PPAR-c agonists increased eNOS activity in normal PAEC and in PAEC from lambs with PPHN. These findings may indicate that a combination of PPAR-c agonists and bosentan could be a future treatment option for PPHN. Currently, no studies involving human beings had been conducted. As described in the section above, PPAR-c agonists may be a future treatment combined with Rho-kinase inhibitors. Compounds that act as PPAR-c agonists are rosiglitazone and 15D-prostaglandin-J2 [100] .
Discussion
According to the literature, sildenafil is the most investigated drug together with iNO in the treatment of PPHN. Some clinical trials investigating the treatment of PPHN can be found on Clinicaltrials.gov [101] (table 2) . Six studies investigated the use of sildenafil either as monotherapy compared to placebo, or as adjuvant therapy to iNO. But sildenafil has the disadvantage of requiring endogenous NO or natriuretic peptides to work in the pulmonary circulation.
The development of increased pulmonary vascular resistance may rely on malfunctioning intracellular pathways due to genetic variations, for example a malfunction of eNOS. Therefore, other treatments instead of sildenafil should be investigated. For instance, sGC activators may be promising drugs, because they are potentially better than sildenafil when fig. 1 and table 3 ). More double-blinded RCTs should be conducted, focusing on mortality, requirement for ECMO, frequently measured oxygenation index improvements compared to iNO within the first days of administration, adverse events and long-term sequelae especially neurodevelopmental. The overall problem with describing adverse effects in the treatment of PPHN is the low prevalence, which may result in an underestimation of adverse effects due to a small sample size. Nevertheless, some adverse events to the treatments have been reported. The adverse event profiles are summarized in table 1. These adverse event profiles indicate that some drugs may be superior to others in terms of adverse events when treating an infant with PPHN, who is a nonresponder to iNO. Hypotension is the common adverse event of each drug; thus, blood pressure should be monitored to prevent development of shock and hypoperfusion in the hypoxic infant. Future studies with sufficient sample sizes should ensure to investigate adverse event profiles as secondary aim of the intervention drugs, as this is important knowledge for choosing a treatment alternative to iNO. To investigate the adverse events of drugs used in the treatment of PHHN, we suggest making a systematic database for registering the adverse events of treatments in PPHN. This would be an opportunity to investigate PPHN properly even though the prevalence is low. Methodological information should be detailed to raise the quality of evidence if the RCTs are included in future systematic reviews and meta-analyses. Researchers should mention whether infants have received surfactant or not and be aware that PPHN with CDH should be investigated separately (table 3) . To evaluate long-term effects, for example neurodevelopment, follow-up is required.
Conclusions
Nowadays, the general management of PPHN relies on treating hypoxaemia and the underlying condition besides maintaining haemoglobin, glucose, intravascular volume, temperature and electrolytes. Infants with PPHN have shown to respond positively to the treatment of high-frequency ventilation combined with iNO. ECMO is a complex and invasive technique which has shown to reduce mortality when used for treating PPHN. iNO is the most investigated choice of treatment and the only approved specific pulmonary vasodilator for newborns. iNO should be considered for infants with hypoxaemic respiratory failure with or without PPHN; 30% of the patients are non-responsive to iNO. Literature reports the use of sildenafil, prostaglandins, milrinone and bosentan as alternative treatment to iNO. These drug choices have different profiles of adverse events (table 3) . A common adverse event for each drug is hypotension, which may be unwanted in a hypoxic infant with PPHN due to the risk of developing shock and hypoperfusion. On Clinicaltrials.gov, sildenafil is the most investigated non-iNO treatment. Animal studies have proven that other treatments of PPHN may emerge in the future. These promising choices consist of sGC activators and stimulators, rhSOD, L-citrulline, Rho-kinase inhibitors and PPAR-c agonists. sGC activators and stimulators and Rho-kinase inhibitors are known in the treatment of pulmonary hypertension in adults. This MiniReview and the findings on Clinicaltrials.-gov are consistent in pointing out that implications for future research are to investigate every aspect of each one of the previously described current and future treatment options for PPHN, except from iNO ( fig. 1) . The treatments and suggested implications for future research are summarized in table 3. We suggest making a multi-centre global database for registering adverse events of treatments for PPHN to avoid underestimations due to the low prevalence.
Outlook
There are many small studies, and we lack a systematic and prioritized effort to perform larger clinical studies in this area. One problem future researchers may encounter will be the long period of recruitment for a sufficient power due to the low incidence of PPHN. The use of sildenafil, prostaglandins, milrinone and bosentan for PPHN as treatment alternate to iNO is commonly reported. Current literature lacks sufficiently conducted double-blinded RCTs investigating these choices with a sufficient sample size and long-term follow-up. If future RCTs testing these drugs are conducted, new beneficial or adverse effects may be reported in the treatment of PPHN. These drugs could be tested either versus placebo or iNO. This will improve the possible choices of treatment when neonates with PPHN are non-responders to iNO. sGC activators sGC stimulators as riociguat are already used as either monotherapy or in combination with ETRA in the treatment of arterial pulmonary hypertension in adults [76] . No paediatric studies using riociguat in the treatment of PPHN were performed.
